IPP Bureau
Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22
By IPP Bureau - August 04, 2021
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Mindpeers launches on-demand behavioural healthcare platform
By IPP Bureau - August 04, 2021
It is designed to tackle mental health issues
Evexia Lifecare to manufacture API of Isometa
By IPP Bureau - August 03, 2021
Robust demand for the product across the Middle East, Africa and Latin America
Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
By IPP Bureau - August 03, 2021
Nureca Ltd has reported financial results for the period ended June 30, 2021.
PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya
By IPP Bureau - August 03, 2021
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
By IPP Bureau - August 03, 2021
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Abbott's Freestyle Libre 2 Ios App Cleared In U.S
By IPP Bureau - August 03, 2021
FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms
NPPA monitors and caps prices of essential drugs: Mandaviya
By IPP Bureau - August 03, 2021
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
Healthium Medtech acquires SGK Lab’s AbGel gelatin business
By IPP Bureau - August 03, 2021
Complementary business models are the reason for the acquisition
Meddo acquires Doxper in a cash and stock deal
By IPP Bureau - August 03, 2021
This deal makes Meddo, one of the largest health-tech players in India
API exports surpass imports by value in 2020-21
By IPP Bureau - August 03, 2021
The govt has rolled out three schemes for promoting the manufacture of API
Drug exports grow on the back of govt support
By IPP Bureau - August 03, 2021
Drug formulations and biologics make impressive gains
AYUSH 64 effective in mild and moderate COVID 19
By IPP Bureau - August 03, 2021
It works as an adjunct to standard care based on robust clinical trials
Glenmark signs agreement with SaNOtize to manufacture NONS
By IPP Bureau - August 02, 2021
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Ajanta Pharma aims to file 10-12 ANDAs per annum
By IPP Bureau - August 02, 2021
India business is growing as per projections; whereas US business will bounce back soon.
